Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
about
Recent Progress in Light-Triggered Nanotheranostics for Cancer Treatment.Nanoparticle contrast agents for computed tomography: a focus on micellesHigh-Density Lipoproteins: Nature's Multifunctional NanoparticlesIsolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with apolipophorin-IIIEvaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platformPerspectives and opportunities for nanomedicine in the management of atherosclerosis.Equilibrium and kinetic studies of the interactions of a porphyrin with low-density lipoproteins.Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.Lipoproteins: When size really matters.Ganglioside embedded in reconstituted lipoprotein binds cholera toxin with elevated affinityRerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cellsCurrent prodrug strategies via membrane transporters/receptors.Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugsStoichiometry of reconstituted high-density lipoproteins in the hydrated state determined by photon antibunchingLow Density Lipid Nanoparticles for Solid Tumor Targeting.Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver.Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs.Nanovehicular intracellular delivery systems.In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes.Lipoprotein-inspired nanoparticles for cancer theranosticsNanoparticles as delivery carriers for anticancer prodrugs.Phospholipid nanodisc engineering for drug delivery systems.The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics.Lipid-based nanoparticles in the systemic delivery of siRNA.Micro- and nanotechnologies for intracellular delivery.Learning from biology: synthetic lipoproteins for drug delivery.Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.Lipoproteins and lipoprotein mimetics for imaging and drug delivery.Preparation, characterization and in vitro-targeted delivery of novel Apolipoprotein E-based nanoparticles to C6 glioma with controlled size and loading efficiency.Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.HDL as a contrast agent for medical imaging.Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment.Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.Liposome Formulations of Hydrophobic Drugs.A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1/21-47 domain of hepatitis B virus.Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particlesMammaglobin as a potential molecular target for breast cancer drug delivery.Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein.
P2860
Q26746178-51142F26-4370-4C33-9789-34D620CAEC13Q26863316-8AD05C76-AF7F-49B2-A58C-09B2433FA6DBQ28077290-0B659CA0-E8B1-4C2E-8D08-D5AB9ADBBEA0Q28474859-2E978752-DC8B-4387-A306-C5B62DB74889Q28541661-59A7579E-A960-46E3-A45B-F4E4226A5C88Q30455490-C0841A02-8895-4D78-BD95-F7932071E888Q30877374-4B0CD445-18E8-452E-A0FF-55FC1316EC17Q33766617-6D05F23B-5F52-40E2-987D-9BA701A178F7Q33947533-235A588B-B025-42BF-945D-F30C8C357095Q34053156-E7E793DB-66A9-4EFD-ADB3-B43D8EEB40C4Q34201954-9E0D40DD-E227-4A9F-B79A-CB422B2C4AC6Q34605627-64E81716-D8A8-492D-836E-C47CF54E4B35Q34779782-9D50DFF2-9E7A-4F0A-9F74-BB0C11371470Q34800220-6AA34088-9D40-4D02-A412-31AE1AF577FDQ35218348-64DC1B5F-7700-44F9-BBCD-CEFBC2E2FBFAQ35747597-3C977FF4-61BF-4C7B-91BB-0B8FFFF5745DQ36148570-CE5A51D2-B343-4278-9842-0F2DE18D87ACQ36840545-95B3D743-7CD9-4C1C-9833-32BD13761950Q36985913-61EE86C8-BB27-445E-849C-D4172C3FABD3Q37058812-91F0E41D-87F0-4461-89EF-0F65BC1C31A4Q37766555-AECCCC7C-C96A-49C0-94B9-FA6091D813A5Q37873918-86EB4825-E283-4169-9AD9-44ED2BB41081Q38002956-9AF42C7C-A8ED-4E5D-86AB-9BA6AC8D5EF7Q38009775-8E776AFF-5CFB-469F-B12E-4C4C95812C6BQ38149124-A4B438BB-4720-41AE-A7F1-8FF7734E0CBCQ38172634-FB922F60-3CB8-4AC4-AEE6-0F35327944FBQ38244304-3B47A2FA-A2D4-4B79-846C-57F6C75FC158Q38262882-AF124E5D-0BE7-4DE8-9F13-947A044E3D3EQ38548184-D3131702-F7FB-4CD5-9535-2C26F793364EQ38822339-514FBD16-823A-4A6F-8796-0744654A6EAAQ38841215-199B88F2-FC61-40AB-8A1E-6E2731EB8805Q39086982-FB6913A7-8A1D-47A1-8E77-3F2F0A1DC96CQ39813598-0BA4DF4F-8520-4F01-8195-90EA42A98315Q40023477-AA55D050-54E0-4D9E-949A-8F5E5432B076Q40175554-9CCBA6FE-38A2-4960-B032-83AACF747716Q40454784-710955A8-44F6-454B-842D-15256DE7026EQ41758629-739F43E5-7EFE-4BFB-B2B7-1663393DA926Q41947556-86CCE1E4-28A6-49D5-9D4F-D09770179B46Q42049927-EDD1B07A-E5EB-4D5C-9913-22EDA3739D83Q42140359-9FDC4D88-29CE-4328-82A3-32E50B300B62
P2860
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@ast
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@en
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@nl
type
label
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@ast
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@en
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@nl
prefLabel
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@ast
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@en
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
@nl
P2093
P1476
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting
@en
P2093
E A Biessen
M K Bijsterbosch
R L de Vrueh
T J van Berkel
P304
P356
10.1016/S0169-409X(01)00109-0
P407
P50
P577
2001-04-01T00:00:00Z